Antigen Information

General Information of This Antigen
Antigen ID
TAR0GJMYC
Antigen Name
Tumor-associated calcium signal transducer 2 (TACSTD2); Programmed cell death 1 ligand 1 (PD-L1)
Gene Name
TACSTD2; CD274
Gene ID
4070 , 29126
Synonym1
B7H1, PDCD1L1, PDCD1LG1, PDL1
Sequence1
MARGPGLAPPPLRLPLLLLVLAAVTGHTAAQDNCTCPTNKMTVCSPDGPGGRCQCRALGS
GMAVDCSTLTSKCLLLKARMSAPKNARTLVRPSEHALVDNDGLYDPDCDPEGRFKARQCN
QTSVCWCVNSVGVRRTDKGDLSLRCDELVRTHHILIDLRHRPTAGAFNHSDLDAELRRLF
RERYRLHPKFVAAVHYEQPTIQIELRQNTSQKAAGDVDIGDAAYYFERDIKGESLFQGRG
GLDLRVRGEPLQVERTLIYYLDEIPPKFSMKRLTAGLIAVIVVVVVALVAGMAVLVITNR
RKSGKYKKVEIKELGELRKEPSL

    Click to Show/Hide
Sequence2
MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL
ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG
DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA
LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC
AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP
YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN
IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP
DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV
PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC
VEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC
PSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG
ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL
RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP
YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR
LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT
HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM
IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA
EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG
AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV
NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ
GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV

    Click to Show/Hide
Family1
EPCAM family
Family2
BTN/MOG family
Function1
May function as a growth factor receptor.

    Click to Show/Hide
Function2
The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function.

    Click to Show/Hide
Uniprot Entry
TACD2_HUMAN , PD1L1_HUMAN
HGNC ID
HGNC:11530 , HGNC:17635
KEGG ID
hsa:4070 , hsa:29126
Each Antibody-drug Conjuate AND It's Component Related to This Antigen
Full List of The ADC Related to This Antigen
Anti-Trop-2 mAb
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
FDA018
SN-38
DNA topoisomerase 1 (TOP1)
An acid-cleavable linker
Anti-TROP2 antibody
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
MK-6837
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
ASP2998
Undisclosed
Stimulator of interferon genes protein (STING1)+DNA topoisomerase 1 (TOP1)
Undisclosed
 ADC Info 
BIO-106
TAMTM
Microtubule (MT)
A non-cleavable linker
 ADC Info 
Sacituzumab drozuntecan
P1021
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
 ADC Info 
MHB036C
MH30010008
DNA topoisomerase 1 (TOP1)
Stable cleavable linker
 ADC Info 
9MW2921
Mtoxin
DNA topoisomerase 1 (TOP1)
A cleavable linker
 [1]
 ADC Info 
GQ1010
Camptothecin analog
DNA topoisomerase 1 (TOP1)
A cleavable open-ring linker
 ADC Info 
BAT8008
Exatecan
DNA topoisomerase 1 (TOP1)
Maleimide tetrapeptide-based cleavable linker
 ADC Info 
FZ-AD004
DXd
DNA topoisomerase 1 (TOP1)
Mc-Val-Ala-PABC double self-immolative linker
 ADC Info 
BL-M08D1
Ed-04
DNA topoisomerase 1 (TOP1)
Gly-Mal-Gly-Gly-Phe-Gly
 ADC Info 
DXC1002
CPT113
DNA topoisomerase 1 (TOP1)
CrossConju linker
 ADC Info 
DAC-002
Tubulysin 196
Microtubule (MT)
2,3-disubstituted long side-chain hydrolysis-resistant linker
 ADC Info 
BAT8003
Batansine
Microtubule (MT)
Maleimido-caproyl
 ADC Info 
XYD-9668-198
Undisclosed
Undisclosed
A cleavable linker
 [2]
 ADC Info 
IBI130
NT1
DNA topoisomerase 1 (TOP1)
A cleavable linker
 [3]
 ADC Info 
HS-20105
TOP1 inhibitor
DNA topoisomerase 1 (TOP1)
A cleavable linker
Anti-TROP2 IgG1 mAb
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
ESG401
SN-38
DNA topoisomerase 1 (TOP1)
A proprietary stable-cleavable linker
Anti-TROP2 mAb
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
OBI-902
Exatecan
DNA topoisomerase 1 (TOP1)
A cleavable linker
 [4]
 ADC Info 
ESG406
Exatecan
DNA topoisomerase 1 (TOP1)
A cleavable linker
Datopotamab
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
Datopotamab deruxtecan
DXd
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
LCB84
MMAE
Microtubule (MT)
β-glucuronide linker
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
BL-M02D1
Ed-04
DNA topoisomerase 1 (TOP1)
Cathepsin B cleavable linker
PF-06478924
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
PF-06664178
Auristatin 0101 (Aur0101)
Microtubule (MT)
AcLys-Val-Cit-PABC
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
OBI-992
Exatecan
DNA topoisomerase 1 (TOP1)
Mal-PEG24-Val-Ala-PABC
Sacituzumab
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
Sacituzumab govitecan
SN-38
DNA topoisomerase 1 (TOP1)
CL2A
 [5]
 ADC Info 
Sacituzumab tirumotecan
KL610023
DNA topoisomerase 1 (TOP1)
Pyrimidine CL2A carbonate linker
 ADC Info 
KH815
Exatecan; Triptolide
DNA topoisomerase 1 (TOP1)+RNA polymerase II
Mc-PEG2-VA-PAB+DBCO-PEG4-GGFG
 [6]
 ADC Info 
sacituzumab vedotin
MMAE
Microtubule (MT)
Mc-Val-Cit-PABC
Tizetatug
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
Tizetatug rezetecan
SHR9265
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
undisclosed
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
ALG01
Undisclosed
Undisclosed
Undisclosed
 [7]
References
Ref 1 Mabwell biopharmaceutical company product pipeline
Ref 2 ADC drug XYD-9668-198 antibody conjugating agent for injection passed the review of the State Drug Administration Drug Review Center and was granted implied permission for clinical trials.
Ref 3 Innoventbio 2022 Annual Performance Report.
Ref 4 OBI-902, a novel TROP2 targeted antibody-drug conjugate via GlycOBI® platform, has favorable pharmacokinetics and sustained antitumor activities in challenging solid tumors
Ref 5 Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
Ref 6 KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model
Ref 7 ALG01, a next-generation anti-PD-L1×TROP-2 bispecific antibody-drug conjugate (BiADC) with STAR technology, demonstrated excellent anti-tumor efficacy & safety in preclinical studies